Apostolos Tsimploulis1,2,3, Phillip H Lam1,2,3, Cherinne Arundel1,2,4, Steven N Singh1,2, Charity J Morgan1,5, Charles Faselis1,4, Prakash Deedwania1,6, Javed Butler7,8, Wilbert S Aronow9,10, Clyde W Yancy11,12, Gregg C Fonarow13,14, Ali Ahmed1,4,5. 1. Veterans Affairs Medical Center, Washington, DC. 2. Georgetown University, Washington, DC. 3. MedStar Washington Hospital Center, Washington, DC. 4. George Washington University, Washington, DC. 5. University of Alabama at Birmingham, Birmingham. 6. University of California-San Francisco, Fresno. 7. Stony Brook University, Stony Brook, New York. 8. University of Mississippi, Jackson. 9. Westchester Medical Center, Valhalla, New York. 10. New York Medical College, Valhalla. 11. Northwestern University, Chicago, Illinois. 12. Deputy Editor. 13. Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California, Los Angeles. 14. Associate Editor for Health Care Quality and Guidelines.
Abstract
Importance: Lower systolic blood pressure (SBP) levels are associated with poor outcomes in patients with heart failure. Less is known about this association in heart failure with preserved ejection fraction (HFpEF). Objective: To determine the associations of SBP levels with mortality and other outcomes in HFpEF. Design, Setting, and Participants: A propensity score-matched observational study of the Medicare-linked Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry included 25 354 patients who were discharged alive; 8873 (35.0%) had an ejection fraction of at least 50%, and of these, 3915 (44.1%) had stable SBP levels (≤20 mm Hg admission to discharge variation). Data were collected from 259 hospitals in 48 states between March 1, 2003, and December 31, 2004. Data were analyzed from March 1, 2003, to December 31, 2008. Exposure: Discharge SBP levels less than 120 mm Hg. A total of 1076 of 3915 (27.5%) had SBP levels less than 120 mm Hg, of whom 901 (83.7%) were matched by propensity scores with 901 patients with SBP levels of 120 mm Hg or greater who were balanced on 58 baseline characteristics. Main Outcomes and Measures: Thirty-day, 1-year, and overall all-cause mortality and heart failure readmission through December 31, 2008. Results: The 1802 matched patients had a mean (SD) age of 79 (10) years; 1147 (63.7%) were women, and 134 (7.4%) were African American. Thirty-day all-cause mortality occurred in 91 (10%) and 45 (5%) of matched patients with discharge SBP of less than 120 mm Hg vs 120 mm Hg or greater, respectively (hazard ratio [HR], 2.07; 95% CI, 1.45-2.95; P < .001). Systolic blood pressure level less than 120 mm Hg was also associated with a higher risk of mortality at 1 year (39% vs 31%; HR, 1.36; 95% CI, 1.16-1.59; P < .001) and during a median follow-up of 2.1 (overall 6) years (HR, 1.17; 95% CI, 1.05-1.30; P = .005). Systolic blood pressure level less than 120 mm Hg was associated with a higher risk of heart failure readmission at 30 days (HR, 1.47; 95% CI, 1.08-2.01; P = .02) but not at 1 or 6 years. Hazard ratios for the combined end point of heart failure readmission or all-cause mortality associated with SBP level less than 120 mm at 30 days, 1 year, and overall were 1.71 (95% CI, 1.34-2.18; P < .001), 1.21 (95% CI, 1.07-1.38; P = .004), and 1.12 (95% CI, 1.01-1.24; P = .03), respectively. Conclusions and Relevance: Among hospitalized patients with HFpEF, an SBP level less than 120 mm Hg is significantly associated with poor outcomes. Future studies need to prospectively evaluate optimal SBP treatment goals in patients with HFpEF.
Importance: Lower systolic blood pressure (SBP) levels are associated with poor outcomes in patients with heart failure. Less is known about this association in heart failure with preserved ejection fraction (HFpEF). Objective: To determine the associations of SBP levels with mortality and other outcomes in HFpEF. Design, Setting, and Participants: A propensity score-matched observational study of the Medicare-linked Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry included 25 354 patients who were discharged alive; 8873 (35.0%) had an ejection fraction of at least 50%, and of these, 3915 (44.1%) had stable SBP levels (≤20 mm Hg admission to discharge variation). Data were collected from 259 hospitals in 48 states between March 1, 2003, and December 31, 2004. Data were analyzed from March 1, 2003, to December 31, 2008. Exposure: Discharge SBP levels less than 120 mm Hg. A total of 1076 of 3915 (27.5%) had SBP levels less than 120 mm Hg, of whom 901 (83.7%) were matched by propensity scores with 901 patients with SBP levels of 120 mm Hg or greater who were balanced on 58 baseline characteristics. Main Outcomes and Measures: Thirty-day, 1-year, and overall all-cause mortality and heart failure readmission through December 31, 2008. Results: The 1802 matched patients had a mean (SD) age of 79 (10) years; 1147 (63.7%) were women, and 134 (7.4%) were African American. Thirty-day all-cause mortality occurred in 91 (10%) and 45 (5%) of matched patients with discharge SBP of less than 120 mm Hg vs 120 mm Hg or greater, respectively (hazard ratio [HR], 2.07; 95% CI, 1.45-2.95; P < .001). Systolic blood pressure level less than 120 mm Hg was also associated with a higher risk of mortality at 1 year (39% vs 31%; HR, 1.36; 95% CI, 1.16-1.59; P < .001) and during a median follow-up of 2.1 (overall 6) years (HR, 1.17; 95% CI, 1.05-1.30; P = .005). Systolic blood pressure level less than 120 mm Hg was associated with a higher risk of heart failure readmission at 30 days (HR, 1.47; 95% CI, 1.08-2.01; P = .02) but not at 1 or 6 years. Hazard ratios for the combined end point of heart failure readmission or all-cause mortality associated with SBP level less than 120 mm at 30 days, 1 year, and overall were 1.71 (95% CI, 1.34-2.18; P < .001), 1.21 (95% CI, 1.07-1.38; P = .004), and 1.12 (95% CI, 1.01-1.24; P = .03), respectively. Conclusions and Relevance: Among hospitalized patients with HFpEF, an SBP level less than 120 mm Hg is significantly associated with poor outcomes. Future studies need to prospectively evaluate optimal SBP treatment goals in patients with HFpEF.
Authors: María T Vidán; Héctor Bueno; Yongfei Wang; Geoffrey Schreiner; Joseph S Ross; Jersey Chen; Harlan M Krumholz Journal: Eur J Heart Fail Date: 2010-02 Impact factor: 15.534
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: J Am Coll Cardiol Date: 2017-04-28 Impact factor: 24.094
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: J Am Coll Cardiol Date: 2017-11-13 Impact factor: 24.094
Authors: Maciej Banach; Vikas Bhatia; Margaret A Feller; Marjan Mujib; Ravi V Desai; Mustafa I Ahmed; Jason L Guichard; Inmaculada Aban; Thomas E Love; Wilbert S Aronow; Michel White; Prakash Deedwania; Gregg Fonarow; Ali Ahmed Journal: Am J Cardiol Date: 2011-02-04 Impact factor: 2.778
Authors: Ali Ahmed; Ahsan Husain; Thomas E Love; Giovanni Gambassi; Louis J Dell'Italia; Gary S Francis; Mihai Gheorghiade; Richard M Allman; Sreelatha Meleth; Robert C Bourge Journal: Eur Heart J Date: 2006-05-18 Impact factor: 29.983
Authors: Mihai Gheorghiade; William T Abraham; Nancy M Albert; Barry H Greenberg; Christopher M O'Connor; Lilin She; Wendy Gattis Stough; Clyde W Yancy; James B Young; Gregg C Fonarow Journal: JAMA Date: 2006-11-08 Impact factor: 56.272
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Eduardo Nunez; Clyde W Yancy; James B Young Journal: Eur Heart J Date: 2008-05-15 Impact factor: 29.983
Authors: Lebogang Mokotedi; Sulé Gunter; Chanel Robinson; Frederic Michel; Ahmed Solomon; Gavin R Norton; Angela J Woodiwiss; Linda Tsang; Patrick H Dessein; Aletta M E Millen Journal: J Cardiovasc Transl Res Date: 2019-05-22 Impact factor: 4.132
Authors: Amanda K Verma; Jie-Lena Sun; Adrian Hernandez; John R Teerlink; Phillip J Schulte; Justin Ezekowitz; Adriaan Voors; Randall Starling; Paul Armstrong; Christopher M O'Conner; Robert J Mentz Journal: Clin Cardiol Date: 2018-07-17 Impact factor: 2.882
Authors: Essraa Bayoumi; Phillip H Lam; Daniel J Dooley; Steven Singh; Charles Faselis; Charity J Morgan; Samir Patel; Helen M Sheriff; Selma F Mohammed; Carlos E Palant; Bertram Pitt; Gregg C Fonarow; Ali Ahmed Journal: Am J Med Date: 2018-09-19 Impact factor: 4.965
Authors: Charles Faselis; Phillip H Lam; Michael R Zile; Poonam Bhyan; Apostolos Tsimploulis; Cherinne Arundel; Samir Patel; Peter Kokkinos; Prakash Deedwania; Deepak L Bhatt; Qing Zeng-Trietler; Charity J Morgan; Wilbert S Aronow; Richard M Allman; Gregg C Fonarow; Ali Ahmed Journal: Am J Med Date: 2020-09-30 Impact factor: 4.965